Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants

被引：0

作者：

Ehrenpreis, Eli D. ^{[1
]}

Sifuentes, Humberto ^{[1
]}

Ehrenpreis, Jamie E. ^{[1
]}

Smith, Zachary L. ^{[1
]}

Marshall, Mike L. ^{[1
]}

机构：

[1] NorthShore Univ Hlth Syst, Highland Pk Hosp, Ctr Study Complex Dis, Highland Pk, IL 60035 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2012年 / 11卷 / 02期

关键词：

adverse drug reactions; adverse events reporting system; FDA; nurse practitioners; pharmacology; pharmacovigilence; physician assistants; side effects; DRUG EVENTS; IMPACT;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objectives: The Adverse Events Reporting System (AERS) of the FDA is used to identify toxicities of drugs that are on the market. Nurse practitioners (NP) and physician assistants (PA), having an increasing role in the delivery of medical care, are also needed to participate in post-marketing pharmacovigilance. This study was performed to assess awareness and use of the AERS in voluntary reporting of drug toxicities by NPs and PAs. Methods: A cluster sample survey was issued at the Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant course in August 2010. The survey assessed familiarity with the AERS, the number of adverse events seen and the frequency of reports sent to the AERS. NP and PA responses were compared using the two-tailed Fisher's exact. Results: Of the 92 respondents, 67 (72%) were NPs and 24 (26%) PAs. Of the 50 (54%) respondents that reported being familiar with the AERS system, 20 (40%) incorrectly identified the methods to report using the AERS. Overall reporting of adverse events was low, particularly in respondents seeing 5-12 adverse events per year. Conclusion: The study suggests that improved education regarding the importance of using AERS for pharmacovigilance is suggested for NPs and PAs. Due to the small size of the study, these data should be viewed as preliminary, pending a larger confirmatory study.

引用

页码：177 / 183

页数：7

共 50 条

[1] Adverse Events of Desvenlafaxine Using FDA Adverse Events Reporting System
Karydes, H. C.
Leikin, J. B.
[J]. CLINICAL TOXICOLOGY, 2010, 48 (06) : 664 - 664
[2] Reporting Adverse Events for Cannabis to the FDA
Hines, Michelle C.
Harinstein, Lisa M.
Kortepeter, Cindy M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 98 - 98
[3] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
Jow, Steven
Hutfless, Susan
[J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
[4] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
Altman, Keith
Budny, Renata
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400
[5] A physician-based voluntary reporting system for adverse events and medical errors
Weingart, SN
Callanan, LD
Ship, AN
Aronson, MD
[J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2001, 16 (12) : 809 - 814
[6] A physician-based voluntary reporting system for adverse events and medical errors
Saul N. Weingart
Lawrence D. Callanan
Amy N. Ship
Mark D. Aronson
[J]. Journal of General Internal Medicine, 2001, 16 : 809 - 814
[7] PHARMACOVIGILANCE ANALYSIS OF FDA ADVERSE EVENTS REPORTING SYSTEM FOR MAVACAMTEN
Matai, Pallavi
Amirian, Aslan
Khadka, Sulochana
Gavilanes, Diana
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 560 - 560
[8] Adverse events reporting
Higuchi, K.
[J]. CLINICAL DRUG INVESTIGATION, 2007, 27 (03) : 225 - 225
[9] Adverse Events Reporting
K. Higuchi
[J]. Clinical Drug Investigation, 2007, 27 : 225 - 225
[10] Reporting of adverse events
Woolf, A
Litovitz, T
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14): : 1410 - 1411

← 1 2 3 4 5 →